Featured Articles

  1. Bridging Clinical And Commercial Needs 1/29/2025

    Discover how viral vector CDMO services can provide a solution to streamline gene therapy development, balancing clinical and commercial needs, to reduce delays and costs.

  2. How To Prevent Protein Aggregation Through Stabilizers And Surfactants 1/13/2025

    Learn about protein aggregation mechanisms, the role of excipients in stabilization, and novel surfactants that prevent aggregation in therapeutic protein formulations in this webinar.

  3. Optimizing Poloxamer 188 1/13/2025

    Poloxamer 188 stabilizes proteins in liquid formulations and protects cells from shear stress. Molecular weight and hydrophobicity variations influence its effectiveness in different biopharmaceutical applications.

  4. Join The Digital Revolution In Supply Chain 12/23/2024

    Explore how the eMERGE™ program digitizes the biopharma supply chain, streamlining raw material receipt, and enhancing efficiency with advanced shipping notifications and integrated systems.

  5. BioPhorum Raw Materials Risk Assessments 12/19/2024

    Torsten Schaderdorf provides an in-depth exploration of current regulations related to Raw Materials Risk Assessment, highlighting the risk criteria and raw material scope outlined in the BioPhorum guidelines.

  6. Assemblies Are Not Particulate Free, Strategies For Risk Mitigation 12/19/2024

    As single-use technologies gain prominence in critical applications, the scrutiny around particulate contamination intensifies due to its potential impact on drug product quality, safety, and patient outcomes.

  7. Transforming The Biopharma Supply Chain, eData Solutions For Agility And Manufacturing Efficiency 12/19/2024

    Explore the role of eData in automating processes, enabling predictive analytics, improving supply chain resilience, and adopting standardized digital platforms in biopharma manufacturing.

  8. Managing Nitrite Impurities: Supplier-Manufacturer View 12/19/2024

    Examine nitrites in excipients, nitrosamine risks, regulatory considerations, analytical controls, and a case study on mitigating risks in pharmaceutical manufacturing and storage.

  9. How Standardized Extractables Data Support E&L Risk Assessment 12/19/2024

    Explore E&L evaluations, USP <665>, supplier-provided extractables data, and collaborative strategies to mitigate risks in Single-Use Systems for biopharmaceutical manufacturing processes.

  10. Evaluating USP 665 For Extractables Testing And Reducing Animal Testing For Biological Reactivity 12/19/2024

    Explore evolving compendial methods, USP <665>, and transitioning to cell-based assays for extractables, leachables, and biological reactivity in single-use pharmaceutical manufacturing.